Indapta Therapeutics Inc. has filed a notice of an exempt offering of securities to raise $51,574,072.00 in New Funding.
According to filings with the U.S. Securities and Exchange Commission, Indapta Therapeutics Inc. is raising up to $51,574,072.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.
About Indapta Therapeutics Inc.
Indapta is a biotechnology company harnessing the natural power of the immune system to fight cancer and autoimmune diseases with its universal natural killer (NK) cell platform derived from healthy donors. The companys allogeneic platform is based on a subset of NK cells that are deficient in the FceR1g protein, and are called g-NK cells (g minus NK cells). These cells are particularly potent at killing cancer cells and autoreactive T and B cells. Indapta is working to bring this off-the-shelf cellular therapy to patients with cancer and autoimmune diseases to address the limitations of currently available therapies. Indapta is based in Houston, TX, and Seattle, WA.
To learn more about Indapta Therapeutics Inc., visit https://indapta.com/
Indapta Therapeutics Inc. Linkedin Page: https://www.linkedin.com/company/indapta-therapuetics/
Contact:
Mark Frohlich, Chief Executive Officer
917-282-9768
https://www.linkedin.com/in/markfrohlich/
SOURCE: http://www.intelligence360.io
Copyright (c) 2025 SI360 Inc. All rights reserved.
